We are so glad you have chosen to visit our community. This site allows open communication, networking, and resource and information sharing between SIG members and site visitors. You can become an active participant in this site by sending your opinions and ideas about topics relating to ambulatory oncology nursing or by sending information on your "best practices" or other information you would like to share.

Please send all information and suggestions to Faye, your Virtual Community Administrator at jazq20a@hotmail.com. Please be sure to include "ONS amb sig" in the subject so it is not sent to junk mail. All input is appreciated.

Faye Flemming

Are you familiar with REMS (Risk Evaluation Mitigation Strategy) ?   REMS is utilized to decrease risk (increase safety) in the ordering and dispensing of certain drugs.  In a recent decision by the FDA, ESA's will be mandated to be ordered and dipensed under a REMS.  A new oncology program, APPRISE ( Assisting Providers and Cancer Patients with Risk Information for Safe Use of ESA's) has been developed to assist with this new mandate. For more information refer to the following links.

• NCCN: Risk Evaluation Mitigation Strategy (REMS) for ESAs Will Impact Oncology Practices
• NCCN Resource Tool: Risk Evaluation & Mitigation Strategies
• FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp